Market Analysis Report Hepatitis C Market | Page 2

with the help of complete report with 70 Pages, figures, graphs and table of contents to analyze the
situations of global Hepatitis C Market and Assessment to 2028.
This report studies the global Hepatitis C Market status and forecast, categorizes the global Hepatitis C
Market size (value & volume), revenue (Million USD), product price by manufacturers, type, application,
and region. Medical Hepatitis C Market Report by Material, Application, and Geography-Global Forecast
to 2028 is an expert and far-reaching research provide details regarding the world’s major provincial
economic situations, concentrating on the principle districts.
Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the
Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the
blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission.
Prevalence of hepatitis C infection among the global populace is increasing. This is mainly caused by
sharing needles, unsterilized medical equipment, and blood transfusion from infected mother to new
born baby. Various companies are getting involved in the development of hepatitis C treatment
medication. This would lead to development of new products, which ultimately drives the market.
Major Players profiled in the Hepatitis C Market report incorporate: Merck & Co, Kenilworth, Roche,
Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson, Bristol-Myers Squibb
Industry News:
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data
for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET™ (glecaprevir/pibrentasvir), in
treatment-naïve patients with compensated cirrhosis. Results from the Phase 3b EXPEDITION-8 study
showed that with 8 weeks of MAVYRET, 100 percent (n=273/273) of genotype 1, 2, 4, 5 and 6 patients
achieved a sustained virologic response 12 weeks after treatment (SVR12) per protocol analysis.
This analysis is part of the ongoing Phase 3b EXPEDITION-8 study evaluating the safety and efficacy of
MAVYRET in treatment-naïve chronic HCV patients with compensated cirrhosis across all major
genotypes (GT1-6).1 The study includes two cohorts; cohort one with genotype 1, 2, 4, 5, 6 chronic HCV-
infected patients, and cohort two with genotype 3 (GT3) chronic HCV-infected patients.
Purchase this report online with 70 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global Hepatitis C Market Report 2019” @ https://www.businessindustryreports.com/buy-
now/164240/single .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Hepatitis C in these regions, from 2014 to 2028 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Report contents include
1 Analysis of Hepatitis C Market including revenues, future growth, market outlook